Introduction

Systemic lupus erythematosus (SLE) is a chronic, systemic, autoimmune inflammatory disease characterized by a wide variety of clinical manifestations that affect multiple systems. The incidence of SLE has a striking 9:1 female predominance. [1,2] Neuropsychiatric involvement is a sign of severe SLE and is the main cause of work loss, with significant physical and psychological burden on patients. [3]

Background:
Conventional magnetic resonance imaging (MRI) is the preferred neuroimaging method in the evaluation of neuropsychiatric systemic lupus erythematosus (NPSLE). The purpose of this study was to investigate the association between clinical and immunological features with MRI abnormalities in female patients with NPSLE, to screen for the value of conventional MRI in NPSLE.

Methods:
A total of 59 female NPSLE patients with conventional MRI examinations were enrolled in this retrospective study. All patients were classified into different groups according to MRI abnormalities. Both clinical and immunological features were compared between MRI abnormal and normal groups. One-way analysis of variance was used to compare the systemic lupus erythematosus disease activity index (SLEDAI) score for MRI abnormalities. Multivariate logistic regression analysis investigated the correlation between immunological features, neuropsychiatric manifestations, and MRI abnormalities.

Results:
Thirty-six NPSLE patients (61%) showed a variety of MRI abnormalities. There were statistically significant differences in SLEDAI scores ($P < 0.001$), incidence of neurologic disorders ($P = 0.001$), levels of 24-h proteinuria ($P = 0.001$) and immunoglobulin M ($P = 0.004$), and incidence of acute confusional state ($P = 0.002$), cerebrovascular disease ($P = 0.004$), and seizure disorder ($P = 0.028$) between MRI abnormal and normal groups. In the MRI abnormal group, SLEDAI scores for cerebral atrophy (CA), cortex involvement, and restricted diffusion (RD) were much higher than in the MRI normal group ($P < 0.001$, $P = 0.002$, $P = 0.038$, respectively). Statistically significant positive correlations between seizure disorder and cortex involvement (odds ratio [OR] = 14.90; 95% confidence interval [CI], 1.50-151.70; $P = 0.023$) and cerebrovascular disease and infratentorial involvement (OR = 10.00; 95% CI, 1.70-60.00; $P = 0.012$) were found.

Conclusions:
MRI abnormalities in NPSLE, especially CA, cortex involvement, and RD might be markers of high systemic lupus erythematosus activity. Some MRI abnormalities might correspond to neuropsychiatric manifestations and might be helpful in understanding the pathophysiology of NPSLE.

Key words: Magnetic Resonance Imaging; Neuropsychiatric Symptoms; Systemic Lupus Erythematosus; Systemic Lupus Erythematosus Disease Activity Index
Neuropsychiatric SLE (NPSLE) has diverse manifestations, varying from focal to diffuse. In 1999, the American College of Rheumatology (ACR) research committee published a set of case definitions for NPSLE manifestations[3] that were divided into 12 central and 7 peripheral nervous system presentations. However, because of the different inclusion criteria and diagnostic methods used, the prevalence of NPSLE ranges from 13% to 91%,[6-10] and only 33–40% of neuropsychiatric manifestations can be attributed directly to primary NPSLE.[2,11]

The pathogenesis of NPSLE is still unknown. Increasing evidence from neuropsychiatric manifestations, imaging, and pathological studies indicate that an immune-mediated pathogenesis might account for NPSLE.[2,3,12] Currently, the diagnosis of NPSLE is determined worldwide by the exclusion of other causes, assessment of clinical and immunological features, analysis of cerebrospinal fluid, electrophysiological studies, and neuroimaging combined[2] but is lacking a gold standard.

Conventional magnetic resonance imaging (MRI) is the preferred neuroimaging method in the evaluation of NPSLE. It is widely available and exceptionally sensitive in some cases of NPSLE such as those with cerebral infarction, hemorrhage, and transverse myelitis. However, its sensitivity for lesions in white matter is low, at only 50–55%.[11] Moreover, MRI abnormalities caused by primary NPSLE lacks specificity, making a differential diagnosis between primary and secondary NPSLE difficult.[13] The validity and importance of MRI in the diagnosis of NPSLE are still not clear.[14] Despite these disadvantages, conventional MRI could be useful to explore pathological mechanisms,[12] facilitate differential diagnosis,[11,15,16] quantify disease activity, and determine the prognosis of NPSLE.[13] MRI often provides a better clue to the underlying causes of clinical manifestations in NPSLE than the manifestations themselves.[17]

In this study, we investigated the association between clinical and immunological features and MRI abnormalities in female patients with NPSLE, to screen for the value of conventional MRI in NPSLE.

**Methods**

In this retrospective study, all SLE inpatients with neuropsychiatric manifestations in Shandong provincial hospital from January 2001 to December 2013 were studied, and therefore informed consent was waived. All patients fulfilled, at least, four of the 11 ACR 1997 revised criteria for the classification of SLE.[18] as well as at least one of the 1999 ACR case definitions[5] for NPSLE manifestations. The neuropsychiatric manifestations of SLE patients were identified and classified by an experienced rheumatologist. The disease duration, clinical manifestations, immunological features, and treatment protocols of patients were recorded, and the SLE disease activity index (SLEDAI) was used.[19] The study protocol was approved by the institutional ethics committee of Shandong Medical Imaging Research Institute, Shandong University.

Exclusion criteria were: age >50 years; cerebral or systemic diseases that could cause neuropsychiatric manifestations, such as cerebral tumor, hypertensive cerebrovascular disease, multiple sclerosis, and reversible posterior leukoencephalopathy syndrome (RPLS); and neuropsychiatric manifestations in SLE patients attributed to secondary NPSLE such as inflammation, electrolyte disturbances, and drug intake.

Conventional MRI examinations were performed in all SLE patients in the study. The examinations were conducted with a 1.5-T device (Siemens Medical Systems, Magnetom Sonata Maestro Class, Germany) or a 3.0-T device (Philips Healthcare, Best, The Netherlands). Axial T1-weighted, T2-weighted, and fluid-attenuated inversion recovery cerebral images were acquired with 5 mm of thickness. Axial diffusion-weighted images (DWI) and apparent diffusion coefficient (ADC) and postcontrast T1-weighted images were also evaluated, if available. All acquired cerebral images were evaluated by an experienced neuroradiologist and were classified into two groups: MRI abnormal and MRI normal. The abnormal group was also classified into different groups according to various MRI abnormalities: periventricular white matter (PVWM) involvement, subcortical white matter (SWM) involvement, cortex involvement, basal ganglia (BG) involvement, infratentorial (IT) involvement, restricted diffusion (RD), and cerebral atrophy (CA). The Fazekas scale was used to determine the extent of PVWM and SWM involvement, which was graded as 0 = absence, 1 = punctate foci, 2 = beginning confluence of foci, and 3 = large confluent areas.[20]

**Statistical analysis**

Categorical data were reported as a percentage, and continuous data as the mean ± standard deviation (SD) or median (range). The normality of the variables was assessed by the Shapiro–Wilk test. Student’s t-test was performed to compare the SLEDAI score between the MRI abnormal and normal groups. The Mann–Whitney U-test was performed to compare the immunological features between two groups. The χ² test was applied to evaluate the association of neuropsychiatric manifestations as independent variables between two groups. The neuropsychiatric manifestations with P < 0.05 were included in the subsequent multivariate logistic regression analysis, and analytical results were presented as the crude odds ratio (OR) and 95% confidence interval (CI).

One-way analysis of variance (ANOVA) was used to compare the SLEDAI score between different MRI abnormalities. The correlation between immunological features, certain neuropsychiatric manifestations, and various MRI abnormalities was also analyzed by using multivariate logistic regression analysis.
All statistical tests were two-sided, and a value of \( P < 0.05 \) was considered as statistically significant. The statistical analysis was carried out using SPSS version 19.0 (SPSS Inc., Chicago, IL, USA).

**Results**

A total of 59 female SLE patients (median age: 24 years) were involved in the study. The median duration from SLE onset to neuropsychiatric events was 5.5 months, ranging from 10 days to 12 years. The mean SLEDAI of these patients was 24.4 ± 11.1. Eleven of 19 ACR neuropsychiatric manifestations were present in the study, of which ten were central and one was peripheral nervous system manifestation. In these 59 patients, the most frequent neuropsychiatric manifestations were a headache (56%), acute confusional state (46%), seizure disorder (29%), and cerebrovascular disease (25%).

Six patients (10%) were diagnosed as having hypertension. However, their onset of neuropsychiatric manifestations was not believed related to high blood pressure. Fifteen patients (25%) had been on steroid therapy before the onset of neuropsychiatric manifestations and none had steroid psychosis. Five (9%) had a history of hypothyroidism that was well-controlled. Two (3%) had a history of diabetes mellitus.

Table 1 shows the clinical and immunological features of NPSLE patients in the MRI abnormal and normal groups. A total 36 NPSLE patients (61%) had an abnormal MRI. Compared with the MRI normal group, patients in the MRI abnormal group had higher SLEDAI scores (\( P < 0.001 \)), higher incidence of neurologic disorders (\( P = 0.001 \)), and higher levels of 24-h proteinuria (\( P = 0.001 \)) and immunoglobulin M (\( P = 0.004 \)). Among the univariate logistic regression analyses of the 11 neuropsychiatric manifestations seen in the study, acute confusional state (\( P < 0.001 \)), cerebrovascular disease (\( P = 0.003 \)), and seizure disorder (\( P = 0.006 \)) were more likely to be present in the MRI abnormal group, with a headache more likely in the MRI normal group (\( P = 0.026 \)). In the subsequent multivariate logistic regression analyses of neuropsychiatric manifestations, the incidence of acute confusional state (\( P = 0.002 \)), cerebrovascular disease (\( P = 0.004 \)), and seizure disorder (\( P = 0.028 \)) showed statistically significant differences between MRI abnormal and normal groups [Table 2].

In the MRI abnormal group, white matter involvement (81%) was the most frequent MRI abnormality, with 19 patients (53%) showing SWM involvement and 15 (42%) showing PVWM involvement. In the SWM involvement group, the frontal lobe was the predilection site, observed in 13 patients (68%), and followed by the temporal and parietal lobes (63%). Most SWM involvement (68%) was bilateral and multiple. Using the Fazekas scale, eight patients (42%) with SWM involvement showed punctate foci (Grade 1), seven patients (37%) showed beginning confluence of foci (Grade 2), and four patients (21%) showed diffuse involvement (Grade 3). In the PVWM involvement group, eight patients (53%) were rated as Grade 1 and seven patients (47%) as Grade 2; 80% of PVWM lesions were bilateral and multiple.

Gray matter involvement (56%) also had visible abnormalities in the MRI abnormal group. Cortex involvement was observed in ten patients (28%), of whom nine (90%) showed diffuse bilateral lesions and one had left frontal lobe involvement; 80% of those with cortex involvement showed corresponding SWM involvement. The PVWM in these ten patients was either not affected or only mildly affected. No predilection sites were found for cortex involvement. BG involvement was observed in 14 patients (39%), of whom ten (71%) showed bilateral BG involvement; all patients had adjacent PVWM involvement [Figure 1].

In addition, DWI and ADC images were available for 28 patients. RD (high DWI and low ADC) was performed in six patients (21%). There were no predilection sites for RD. The size of lesions varied from punctate to patchy. Postcontrast T1-weighted images were also acquired in 12 patients; enhancement was observed in three patients (25%), of whom one had mild enhancement in the bilateral BG region, one had multiple mild enhancement
areas in the bilateral frontal lobe, and one had multiple marked enhancement areas in the cortex of the frontal and temporal lobes.

In addition, nine patients (25%) had IT involvement. The volume of cerebrum was determined by subjective global assessment, and CA was observed in 11 patients (31%). MRI abnormalities are shown in Table 3.

The SLEDAI scores of various MRI abnormalities are shown in Figure 2. In the ANOVA, the SLEDAI scores of CA (34.0 ± 13.2), cortex involvement (33.2 ± 7.6), RD (32.5 ± 10.5), IT involvement (30.8 ± 9.7), and SWM involvement (29.8 ± 10.3) were higher than those in the

---

**Table 1: Clinical and immunological features in MRI abnormal and normal groups of female NPSLE patients**

| Variables                      | MRI abnormal group (n = 36) | MRI normal group (n = 23) | t/Z/χ² | P     |
|--------------------------------|-----------------------------|---------------------------|--------|-------|
| Age (years), median (range)    | 25 (8, 48)                  | 23 (5, 45)                | −0.684 | 0.494 |
| Duration of SLE (months), median (range) | 21.0 (0.3, 240.0) | 3.0 (0.7, 144.0) | −1.179 | 0.238 |
| SLEDAI, mean ± SD             | 28.8 ± 11.5                 | 17.5 ± 7.3                | 4.594* | <0.001|
| CRP (mg/L), median (range)    | 11.3 (0.7, 144.0)           | 4.0 (3.0, 21.4)           | −1.666 | 0.096 |
| ESR (mm/h), median (range)    | 55.0 (5.0, 119.0)           | 33.0 (1.0, 119.0)         | −1.546 | 0.122 |
| Proteinuria (g/24 h), median (range) | 1.0 (0.1, 7.4) | 0.1 (0.02, 1.9) | −3.242 | 0.001 |
| ACR SLE criteria, n (%)       |                             |                           |        |       |
| Malar rash                    | 22 (61)                     | 18 (78)                   | 1.891  | 0.169 |
| Discoid lupus                 | 4 (11)                      | 3 (13)                    | 0.000  | 1.000 |
| Photosensitivity              | 9 (25)                      | 6 (26)                    | 0.009  | 0.925 |
| Oral ulcers                   | 15 (42)                     | 7 (30)                    | 0.757  | 0.384 |
| Arthritis                     | 22 (61)                     | 16 (70)                   | 0.438  | 0.508 |
| Pleuritis or pericarditis     | 6 (17)                      | 3 (13)                    | 0.000  | 0.995 |
| Renal disorders               | 18 (50)                     | 9 (39)                    | 0.668  | 0.414 |
| Neurologic disorder           | 26 (72)                     | 6 (26)                    | 12.035 | 0.001 |
| Hematologic disorder          | 18 (50)                     | 6 (26)                    | 3.326  | 0.068 |
| Immunologic disorder          | 24 (67)                     | 18 (78)                   | 0.920  | 0.338 |
| ANA positive                  | 36 (100)                    | 23 (100)                  | 0.000  | 1.000 |
| Immunological features, median (range) | 260.5 (10.0, 800.0) | 453.3 (10.0, 800.0) | 1.094  | 0.274 |
| Anti-dsDNA (RU/ml)            | 19.6 (2.0, 193.6)           | 25.9 (2.0, 200.0)         | 0.289  | 0.773 |
| ANuA (RU/ml)                  | 24.1 (3.4, 200.0)           | 38.8 (2.0, 200.0)         | 0.550  | 0.582 |
| Anti-RNP (RU/ml)              | 15.0 (2.7, 171.2)           | 24.9 (1.9, 200.0)         | 0.414  | 0.679 |
| AHA (RU/ml)                   | 18.7 (0.9, 172.1)           | 49.9 (2.0, 200.0)         | 1.120  | 0.263 |
| ALC-IGA (U/ml)                | 4.1 (0.9, 13.2)             | 3.9 (1.1, 16.7)           | 0.472  | 0.637 |
| ALC-IGG (U/ml)                | 3.3 (0.6, 39.3)             | 4.8 (1.3, 104.1)          | 1.067  | 0.286 |
| ALC-IGM (U/ml)                | 4.6 (0.5, 58.9)             | 6.3 (0.6, 126.2)          | 0.828  | 0.408 |
| IGA (g/L)                     | 2.4 (0.3, 9.7)              | 2.1 (0.2, 4.1)            | −1.753 | 0.080 |
| IGG (g/L)                     | 17.1 (2.9, 46.6)            | 16.0 (9.2, 29.2)          | 0.642  | 0.521 |
| IGM (g/L)                     | 0.9 (0.2, 6.3)              | 1.7 (0.5, 5.4)            | 2.899  | 0.004 |
| C3 (g/L)                      | 0.5 (0.1, 1.5)              | 0.5 (0.2, 1.6)            | 0.215  | 0.830 |
| C4 (g/L)                      | 0.08 (0.03, 0.4)            | 0.07 (0.05, 0.4)          | −0.451 | 0.652 |
| Neuropsychiatric manifestations, n (%) |                        |                           |        |       |
| Headache                      | 16 (44)                     | 17 (74)                   | 4.944  | 0.026 |
| Seizure disorder              | 15 (42)                     | 2 (9)                     | 7.438  | 0.006 |
| Cerebrovascular disease       | 14 (39)                     | 1 (4)                     | 8.831  | 0.003 |
| Movement disorder             | 1 (29)                      | 0                         | 0.000  | 1.000 |
| Myelopathy                    | 1 (29)                      | 0                         | 0.000  | 1.000 |
| Acute confusional state       | 23 (64)                     | 4 (17)                    | 12.224 | <0.001|
| Psychosis                     | 2 (6)                       | 0                         | 0.170  | 0.680 |
| Mood disorders                | 3 (8)                       | 2 (9)                     | 0.000  | 1.000 |
| Anxiety disorder              | 1 (3)                       | 0                         | 0.000  | 1.000 |
| Cognitive dysfunction         | 1 (3)                       | 0                         | 0.000  | 1.000 |
| Neuropathy, cranial           | 0                           | 2 (9)                     | 1.129  | 0.288 |

Values are presented as a mean ± SD, median (range) or n (%). *: t values; †: Z values; ‡: χ² values. MRI: Magnetic resonance imaging; NPSLE: Neuropsychiatric systemic lupus erythematosus; SLE: Systemic lupus erythematosus; SLEDAI: Systemic lupus erythematosus disease activity index; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; ACR: American College of Rheumatology; ANA: Antinuclear antibody; Anti-dsDNA: Anti-double-stranded DNA; Anti-SM: Anti-Smith; ANuA: Anti-nucleosome antibody; Anti-RNP: Anti-ribonucleoprotein; AHA: Anti-histone antibody; ACL: Anti-cardiolipin; IGA: Immunoglobulin A; IGG: Immunoglobulin G; IGM: Immunoglobulin M; C3: Complement 3; C4: Complement 4; SD: Standard deviation.
In addition, NPSLE patients with cerebrovascular disease had a higher incidence of the following MRI abnormalities: IT involvement (78%), RD (67%), and PVWM involvement (60%). There was a statistically significant positive correlation between cerebrovascular disease and IT involvement (OR = 10.00; 95% CI, 1.70–60.00; P = 0.012). The sensitivity and specificity of IT involvement for cerebrovascular disease in the MRI abnormal group were 50% and 91%.

**Discussion**

In this study, we investigated the relationships between clinical and immunological features and MRI abnormalities in female patients with NPSLE. In the MRI abnormal group, the SLEDAI scores of CA, cortex involvement, and RD were much higher than in the MRI normal group. Statistically significant positive correlations were found between seizure disorder and cortex involvement, and cerebrovascular disease and IT involvement.

MRI abnormalities were found in 61% of NPSLE patients. The percentage was slightly higher than that reported in other recent studies. Conventional MRI is the preferred neuroimaging method for evaluation of NPSLE but has limited sensitivity and specificity. Some new MRI technologies, such as magnetic resonance spectroscopy, magnetization transfer imaging (MTI), and perfusion weighted imaging, might detect more abnormalities in NPSLE patients than conventional MRI, especially those in white matter. However, their sensitivity and specificity for NPSLE need to be confirmed. The most frequent neuropsychiatric manifestations in our study were headache, acute confusional state, seizure disorder, and cerebrovascular disease, which were in

---

**Table 2: Multivariate logistic regression analysis of neuropsychiatric manifestations in MRI abnormal and normal groups**

| Variables | B | Wals | OR | 95% CI    | P   |
|-----------|---|------|----|-----------|-----|
| CVD       | 3.5 | 8.5  | 31.90 | 3.10–326.60 | 0.004 |
| ACS       | 2.4 | 9.2  | 10.50 | 2.30–48.30 | 0.002 |
| Seizure disorder | 2.1 | 4.9 | 8.10 | 1.30–52.00 | 0.028 |

MRI: Magnetic resonance imaging; B: Partial regression coefficient; OR: Odds ratio; CI: Confidence interval; ACS: Acute confusional state; CVD: Cerebrovascular disease.

---

**Table 3: MRI manifestations in 59 SLE female patients**

| Variables | Values |
|-----------|--------|
| Normal MRI | 23 (39) |
| MRI abnormalities | 36 (61) |
| PVWM lesions | 15 (42) |
| Grade 1 | 8 (22) |
| Grade 2 | 7 (19) |
| SWM lesions | 19 (53) |
| Grade 1 | 8 (22) |
| Grade 2 | 7 (19) |
| Grade 3 | 4 (11) |
| Basal ganglia lesions | 14 (39) |
| Cortical lesions | 10 (28) |
| Infratentorial lesions | 9 (25) |
| Cerebral atrophy | 11 (31) |
| Restricted diffusion | 6/28 (21) |
| Contrast enhancement | 3/12 (25) |

Values are presented as n (%) or n/N (%). MRI: Magnetic resonance imaging; SLE: Systemic lupus erythematosus; PVWM: Periventricular white matter; SWM: Subcortical white matter.

MRI normal group (P < 0.001, P = 0.002, P = 0.038, P = 0.028, and P = 0.004, respectively). No significantly statistical difference was found between MRI abnormal groups.

Table 4 shows the association between immunological features, certain neuropsychiatric manifestations, and various MRI abnormalities using multivariate logistic regression analysis. No significant positive correlation was found between immunological features and MRI abnormalities (P > 0.05).

MRI abnormalities including cerebral atrophy (73%), cortex involvement (70%), and RD (67%) were most common in NPSLE patients with acute confusional states. After correction for age and duration dependencies, there was no significant positive correlation between acute confusional states and MRI abnormalities.

The most frequent MRI abnormalities in seizure disorder patients were cortex involvement (90%), IT involvement (67%), and CA (55%). Statistically significant positive correlations between seizure disorder and cortex involvement were found (OR = 14.90; 95% CI, 1.50–151.70; P = 0.023). The sensitivity of cortex involvement for seizure disorder in the MRI abnormal group was 61%, while the specificity was 95%.
Table 4: The association between certain neuropsychiatric manifestations and various MRI abnormalities

| Neuropsychiatric manifestations | MRI abnormalities | B     | Wals  | OR   | 95% CI    | P     |
|---------------------------------|------------------|-------|-------|------|-----------|-------|
| ACS                             | PWVM involvement | −2.9  | 6.3   | 0.06 | 0.01–0.50 | 0.012 |
| Seizure disorder                 |                  | −2.0  | 3.0   | 0.10 | 0.01–1.30 | 0.085 |
|                                 | Cortex involvement | 2.7   | 5.2   | 14.90| 1.50–151.70| 0.023 |
|                                 | Cerebral atrophy  | 2.0   | 3.1   | 7.20 | 0.80–65.60 | 0.080 |
|                                 | PVWM involvement | −2.7  | 4.9   | 0.07 | 0.01–0.70  | 0.027 |
| CVD                             | IT involvement   | 2.3   | 6.3   | 10.00| 1.70–60.00 | 0.012 |
| AHA                             | BG involvement   | −1.9  | 3.6   | 0.15 | 0.02–1.10  | 0.060 |
|                                 | PWVM involvement | 2.1   | 3.4   | 8.50 | 0.90–83.50 | 0.066 |

MRI: Magnetic resonance imaging; B: Partial regression coefficient; OR: Odds ratio; CI: Confidence interval; ACS: Acute confusional state; CVD: Cerebrovascular disease; IT: Infratentorial; BG: Basal ganglia; PVWM: Periventricular white matter; SWM: Subcortical white matter; AHA: Anti-histone antibody; IGA: Immunoglobulin A.

accordance with the data of Steup-Beekman et al.⁹ Headache was one of the most frequent neuropsychiatric manifestations in NPSLE patients in many studies.⁶,¹⁰,¹³,¹ⁱ However, some researchers believed that a headache was frequent in the general population and was usually unrelated to SLE.⁵,¹⁷,¹⁹ In our study, the headache was more likely to be present in the MRI normal group (P = 0.026), indicating a poor correlation between a headache and MRI abnormalities. Moreover, we found the incidence of acute confusional state, cerebrovascular disease, and seizure disorder in the MRI abnormal group was much higher than in the MRI normal group (P < 0.001, P = 0.003, P = 0.006, respectively), which indicated that MRI abnormalities might correspond to certain neuropsychiatric manifestations.

Generalized SLE activity is a major risk factor for SLE-related neuropsychiatric events.²⁷–²⁹ SLEDAI is a validated model for the overall evaluation of disease activity in SLE patients and can be of great use in treatment.¹⁹ In our study, the SLEDAI scores of the MRI abnormal group, especially for those with CA, cortex involvement, and RD were much higher than for the MRI normal group (P < 0.001, P = 0.002, P = 0.038, respectively). The appearance of certain MRI abnormalities might be markers of high SLE activity.

White matter involvement was the most frequent MRI abnormality. The role of white matter involvement in NPSLE was not clear. Similar white matter abnormalities can be found in patients with active NPSLE, in patients with the previous NPSLE and in SLE patients with no neuropsychiatric manifestations. In our study, no significant positive correlations between PVWM or SWM involvement and neuropsychiatric manifestations were found.

Cortex involvement was an important MRI abnormality in NPSLE in our study; 80% of patients with cortex involvement had corresponding SWM involvement, while 20% had none. These differing MRI abnormalities could not be explained by a vascular injury mechanism, indicating other or more diverse pathophysiological mechanisms in NPSLE. Luyendijk et al.¹² also found that 12% of SLE patients in their study had diffuse cortex involvement without SWM involvement, and attributed this striking finding to the immune response against neuronal components. In addition, Steens et al.²⁴ found abnormalities in gray matter in NPSLE patients using MTI, while the white matter was not affected. Cortical involvement in our study supported the possibility that the mechanism might be a response to autoimmune inflammation injury.

DWI and ADC images were particularly effective in identifying certain brain injuries such as acute infarction and hemorrhage. In our study, RD was demonstrated in six patients (21%), four of whom were attributed to acute or subacute infarction, and two to an inflammatory injury, based on MRI abnormalities. Jennings et al.¹³ thought that DWI and ADC images might be a marker of “active” disease and should be taken as an indication for follow-up MRI in the evaluation of NPSLE. We found a high SLEDAI in RD (33.8 ± 13.1). DWI could help distinguish between severe and mild manifestations and could be a valid tool in daily clinical decision making.³⁰

CA has been observed in NPSLE.³¹,³² Compared with controls, NPSLE patients had reduced the cortical thickness and subcortical structure volume. In our study, CA was observed in 11 patients (31%) in the MRI abnormal group. A striking finding was the high SLEDAI of CA (34.0 ± 13.2), which could be regarded as an excellent marker of high SLE activity.

In our study, a significant positive correlation was found between seizure disorder and cortex involvement (P = 0.023). Both the incidence and specificity of cortex involvement for seizure disorder were high (90% and 95%). This indicated a high correlation between seizure disorder and cortex involvement. Cortex involvement might be a risk factor for seizure disorder in NPSLE. A significantly positive correlation was also found between cerebrovascular disease and IT involvement (P = 0.012), which indicated that vasculopathy also played an important role. IT involvement could become a marker of cerebrovascular disease in NPSLE.

There were some limitations in our study. Firstly, the MRI systems that we used were different, and the applied pulse sequences were accordingly inconsistent, which was inevitable in a 13-year retrospective study. Secondly, only
Validation of a disease-specific health-related Neuropsychiatric manifestations in female NPSLE patients were enrolled in the study because of the small quantity of male NPSLE patient. Another limitation was the subjective assessment of CA. Quantitative assessment methods should be used in future studies.

In conclusion, the MRI abnormalities in NPSLE, especially CA, cortex involvement, and RD, might be markers of high SLE activity. Some MRI abnormalities might correspond to certain neuropsychiatric manifestations and might be helpful in understanding the pathophysiology of NPSLE.

Financial support and sponsorship
This study was supported by the Provincial Natural Science Foundation of Shandong (No. ZR2012HM042).

Conflicts of interest
There are no conflicts of interest.

References
1. Sui W, Hou X, Che W, Yang M, Dai Y. The applied basic research of systemic lupus erythematosus based on the biological omics. Genes Immun 2013;14:133-46. doi: 10.1038/genes.2013.3.
2. Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014;10:338-47. doi: 10.1038/nrrheum.2014.15.
3. Conti F, Perricone C, Reboldi G, Gawlicki M, Bartosiewicz I, Pacucci VA, et al. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL‑IT. Lupus 2014;23:743-51. doi: 10.1177/0961203314524466.
4. O’Neill S, Cervera R. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2010;24:841-55. doi: 10.1016/j.berrer.2010.010.006.
5. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608. doi: 10.1002/1529-0131 (199904)42:4<599:AID‑ANR2>3.0.CO; 2‑F.
6. Chiewthanakul P, Sawanyawisuth K, Foocharoen C, Tiamkao S. Neuropsychiatric systemic lupus erythematosus: Magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 2013;12:1166-70. doi: 10.1016/j.autrev.2013.07.004.
7. Katsamata Y, Harigai M, Kawaguchi Y, Fukasawa C, Soejima M, Kanno T, et al. Diagnostic reliability of magnetic resonance imaging for central nervous system syndromes in systemic lupus erythematosus: A prospective cohort study. BMC Musculoskelet Disord 2010;11:13. doi: 10.1186/1471-2474-11-13.
8. Appenzeller S, Costallat LT, Li LM, Cendes F. Magnetic resonance spectroscopy in the evaluation of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum 2006;55:807-11. doi: 10.1002/art.22228.
9. Steens SC, Admiraal‑Behloul F, Bosma GP, Steup‑Beekman GM, Olofsen H, Le Cessie S, et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum 2004;50:2877-81. doi: 10.1002/art.20654.
10. Wang PL, Cagnoli PC, McCune WJ, Schmidt‑Wilecke T, Lowe SE, Graft CC, et al. Perfusion‑weighted MR imaging in cerebral lupus erythematosus. Acad Radiol 2012;19:965‑70. doi: 10.1016/j.acra.2013.02.023.
11. Unterman A, Nolte JE, Boaz M, Abady M, Shenfeld Y, Zandman‑Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: A meta‑analysis. Semin Arthritis Rheum 2011;41:1-11. doi: 10.1016/j.semarthrit.2010.08.001.
12. Akselrud L, Okonkwo DO, Patel S, Kulkarni V, Hietaharju A. The prevalence of neuropsychiatric lupus syndromes in systemic lupus erythematosus. Semin Neuropsychiatry 2001;6:496‑500. doi: 10.1212/WNL.57.3.496.
13. Steup‑Beekman GM, Zirkzee EJ, Cohen DJ, Gahrman BM, Emmer BJ, Steens SC, et al. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: Epidemiology and radiology pointing to an immune‑mediated cause. Ann Rheum Dis 2013;72 Suppl 2:i76-9. doi: 10.1136/annrheumdis-2012-202369.
14. Abdul‑Sattar AB, Goda T, Negm MG. Neuropsychiatric manifestations in a consecutive cohort of systemic lupus erythematosus, a single center study. Int J Rheum Dis 2013;16:715‑23. doi: 10.1111/j.1756‑875X.2012.01213.x.
15. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010;6:358‑67. doi: 10.1038/nrrheum.2010.62.
16. Luyendijk J, Steens SC, Ouwendijk WJ, Steup‑Beekman GM, Bollen EL, van der Grond J, et al. Neuropsychiatric systemic lupus erythematosus: Lessons learned from magnetic resonance imaging. Arthritis Rheum 2011;63:722-32. doi: 10.1002/art.30157.
17. Jennings JE, Sundgren PC, Attwood J, McCune J, Maly P. Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neurol Radiology 2004;46:15-21. doi: 10.1007/s00234‑003‑1049‑2.
18. Pfeffer SF, Selgrade JL, Smedley DA, Cendes F, Kril JJ, Kastner DL. Neuropsychiatric manifestations in systemic lupus erythematosus: Epileptology, pathophysiology and management. CNS Drugs 2011;25:721‑36. doi: 10.2165/11591670‑000000000‑00000.